Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

o fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dep
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
(Date:7/2/2015)... 2015   Decision Resources Group finds ... less frequent dosing as the highest unmet need ... burden on both patients and providers associated with ... injections, which are the current standard of care. ... is in development for dosing every two to ...
(Date:7/2/2015)... June 25, 2015 ... announced the addition of the "2015 ... Global Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in Clinical Chemistry and Immunodiagnostics: ... a new seven-country strategic analysis of major ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich ... be held from March 4th - 6th, the 2016 (a previous announcement had stated ... Designed to take participants from the basic training and fundamentals of nasal surgery through ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County Bar Association ... 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law ... of investigating these types of cases. , Each year, New York State residents ...
(Date:7/3/2015)... ... ... Jennifer Renee Hanes, DO is the new Medical Director of its Sienna Plantation ... emergency rooms in the United States. , “We are excited to welcome Dr. Hanes ... Director of First Choice Emergency Room, Dr. James M. Muzzarelli. , Dr. Hanes ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is ... opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt chain ... 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, will ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetfrog Opens First Location in Mississippi 2
... 50 do not realise that breast cancer is more common as ... about other facts which doctors say could save their lives by ... women over 50 do not check their breasts for changes from ... screening. ,It is hoped the survey, commissioned by charity ...
... year, hundreds of thousands of children go to the emergency ... bones before they’re put in a cast can be excruciating.// ... fraction of the pain. ,There’s no question that broken ... treat, say pediatric emergency specialists. According to specialists there’s a ...
... may be more than skin-deep. Researchers from the University of ... tea, they say could fight skin cancer.// ,Tea contains ... are found in both black and green teas and, unlike ... chemicals are thought to decrease levels of the enzyme JNK-2, ...
... help decrease the risk of breast cancer in postmenopausal women.,Researchers ... 74,000 women who were between ages 50 and 79 years ... physical activity, which was based on how many hours per ... at ages 18, 35 and 50 years was also considered. ...
... genetic makeup of viral particles isolated from humans with SARS ... being held in a retail food market. ,The animals ... percent genetically identical to a virus that causes severe acute ... that the markets provide a venue for the animal (corona ...
... a compromised immune system who have undergone organ transplantation could ... receive the measles, mumps and rubella vaccine in a timely ... among the lowest in the United Kingdom. Just over 60 ... of the vaccine by March 2003. (Data shows there were ...
Cached Medicine News:Health News:SARS research confirms link to animals 2
... The Infinity Uric Acid single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Uric Acid reagent provides ...
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... The Infinity Glucose Oxidase single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Glucose Oxidase reagent provides ...
... Infinity Glucose Hexokinase powder reagent once ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Glucose Hexokinase powder reagent provides ...
Medicine Products: